Antibody–drug conjugates (ADCs) are drawing more clinical research because they combine a target-recognizing antibody with a potent cancer-killing payload. Recent approvals show the approach reaching specific biomarker-defined groups, while trial activity offers a separate sign of development momentum. Neither signal means ADCs work for every cancer—or establishes how large the global ADC market is.
What is an antibody–drug conjugate?
An ADC has three parts: an antibody that recognizes a target protein, a linker that attaches the antibody to a drug, and a cytotoxic payload. The design aims to deliver that payload to cells expressing the target.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Oncologic Critical Care | $1,110.00 | Buy on Amazon |
| 2 |
|
DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Print + eBook with... | $344.47 | Buy on Amazon |
| 3 |
|
Wintrobe's Clinical Hematology: Print + eBook with Multimedia | $396.66 | Buy on Amazon |
| 4 |
|
Geriatric Oncology (Springer Reference) | $1,044.19 | Buy on Amazon |
| 5 |
|
Encyclopedia of Cancer | $1,744.71 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
The American Association for Cancer Research (AACR) describes a sequence in which the ADC binds a target on a cancer-cell surface, enters the cell, and releases its payload after the linker is cleaved. This is targeted drug delivery, not a guarantee that treatment affects only cancer cells or avoids side effects.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Why are ADCs attracting more research?
Clinical-trial activity is increasing
AACR’s 2025 Cancer Progress Report says 284 ADC clinical trials were launched globally in 2024, nearly 100 more than in 2023. AACR characterizes ADCs as the fastest-growing therapeutic approach for solid tumors worldwide. The trial count is evidence of research activity; it does not measure sales, commercial adoption, the chance that a trial will succeed, or patient benefit.
#1 Best Overall
Approvals illustrate the importance of patient selection
ADC approvals can address narrowly defined groups based on cancer type, disease stage, prior treatment, and tumor biomarkers. Two examples described in AACR’s 2025 report illustrate why “an ADC for breast cancer” or “an ADC for lung cancer” is too broad a description:
| Medicine | Group and setting described by AACR | Evidence cited by AACR |
|---|---|---|
| Datopotamab deruxtecan-dlnk (Datroway) | Approved in January 2025 for adults with unresectable or metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer after endocrine-based therapy and chemotherapy. | In the phase III trial supporting the breast-cancer indication, AACR reports nearly seven months without disease progression versus five months with standard chemotherapy. This is a progression-free-survival result, not evidence by itself of longer overall survival; AACR says more research is needed to establish whether overall survival improves. |
| Datopotamab deruxtecan-dlnk (Datroway) | AACR reports a June 2025 expansion for certain adults with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC), after EGFR-targeted therapy and platinum-based chemotherapy. | AACR reports tumor shrinkage in 45% of patients in the cited trials for this NSCLC indication. That response figure applies to the studied population, not to all people with lung cancer. |
| Telisotuzumab vedotin-tllv (Emrelis) | AACR describes approval for locally advanced or metastatic NSCLC after prior systemic therapy when tumors have high MET protein overexpression. | In a phase II trial, AACR reports tumor shrinkage in 35% of patients whose tumors had high MET overexpression. AACR also describes FDA approval of a companion diagnostic assay. |
These examples are not interchangeable: the target or biomarker, cancer subtype, prior treatment, and disease setting help define who was studied and who may be eligible. Approval status and prescribing details can change; the current FDA label and diagnostic requirements are the relevant references for treatment decisions.
Rank #2
What does “growth” mean—and what does it not mean?
Trial launches and regulatory approvals are measures of scientific and development activity, not revenue. A separate count in an American Society of Clinical Oncology (ASCO) review is 14 FDA-approved ADCs as of early 2026. That is a dated count reported in a professional review, not a verified total current through October 2026.
The sources cited here do not establish a current, verified global ADC market-size estimate. Trial volume or the number of approvals cannot substitute for market revenue: they answer different questions. A market estimate would need its own dated source and a clear distinction between recorded sales and forecasts.
How are ADC designs and uses evolving?
ASCO’s May 2026 review discusses bispecific ADCs, constructs carrying dual payloads, combination strategies, and efforts to study ADCs earlier in treatment. These are development directions, not proof that investigational designs are approved or suitable for every cancer. Moving a treatment into an earlier line also requires evidence for that particular disease and patient group.
For any candidate, a useful way to assess the evidence is to ask what target it recognizes and how eligibility is determined; which cancer and treatment setting were studied; what the antibody, linker, and payload are; and whether results come from a response measure, progression-free survival, or overall survival. Trial phase, comparator, follow-up, jurisdiction, and regulatory status matter as well.
Rank #4
Why does FDA guidance matter to ADC development?
In March 2024, the U.S. Food and Drug Administration issued final guidance for ADCs with cytotoxic small-molecule payloads. It identifies clinical-pharmacology questions developers should address, including bioanalytical methods, dosing strategy, dose- and exposure-response, intrinsic factors, QTc assessment, immunogenicity, and drug–drug interactions.
Recommended Free Tools
The guidance is not a universal template for every ADC: FDA cautions that it may not apply to ADCs with other payload types or to indications outside oncology. Its scope reflects a practical point about this drug format: development involves evaluating the conjugate and its pharmacology, not just identifying a tumor target.
Best Value
Sources and limits
The approval examples and trial figures above are reported in AACR’s Cancer Progress Report 2025. The early-2026 approval count and development directions come from ASCO’s review, “Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions,” published May 14, 2026. FDA’s ADC clinical-pharmacology guidance is dated March 2024. Regulatory labels and the ADC pipeline may change after those publications, so dated counts and study results should not be read as a live approval list or individual treatment advice.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
